CAPRICORN CARVEDILOL PDF

Carvedilol significantly reduced mortality from cardiovascular causes and recurrent non-fatal MI. These findings are consistent with previous trials exploring the benefits of beta-blockers in managing acute MI. Carvedilol did, however, significantly decrease mortality from cardiovascular causes and recurrent non-fatal MI. Please click to read study in The Lancet. The co-primary endpoints were 1 all-cause mortality and 2 all-cause mortality and cardiovascular hospital admissions. Secondary endpoints were sudden death and hospital admission for heart failure, while other endpoints were recurrent non-fatal MI and all-cause mortality or recurrent non-fatal MI.

Author:Fenriramar Dilabar
Country:Montenegro
Language:English (Spanish)
Genre:Literature
Published (Last):19 June 2004
Pages:284
PDF File Size:11.82 Mb
ePub File Size:20.71 Mb
ISBN:339-1-30766-739-8
Downloads:32996
Price:Free* [*Free Regsitration Required]
Uploader:JoJolar



Carvedilol significantly reduced mortality from cardiovascular causes and recurrent non-fatal MI. These findings are consistent with previous trials exploring the benefits of beta-blockers in managing acute MI. Carvedilol did, however, significantly decrease mortality from cardiovascular causes and recurrent non-fatal MI. Please click to read study in The Lancet.

The co-primary endpoints were 1 all-cause mortality and 2 all-cause mortality and cardiovascular hospital admissions. Secondary endpoints were sudden death and hospital admission for heart failure, while other endpoints were recurrent non-fatal MI and all-cause mortality or recurrent non-fatal MI. A total of 1, patients were recruited from centres in 17 different countries, and they were followed for a mean of 1.

There were also no significant differences between the two groups in terms of secondary endpoints. Patients in the carvedilol group, however, did experience significantly lower rates of cardiovascular-caused mortality and non-fatal MI. All rights reserved. No works may be reproduced without written consent from 2minutemedicine. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.

No benefit, monetary or otherwise, is realized by any participants or the owner of this domain. Thursday, June 4, Carotid endarterectomy and medical therapy reveal similar effectiveness in asymptomatic carotid…. Early administration of thrombolytics in ischemic stroke associated with reduced all-cause…. Despite increasing cost of insulin, out-of-pocket expenses stable from The Classics General Medicine Classics.

Cervical length indicates risk of preterm delivery [Classics Series]. All-time hits. The Child-Pugh score: Prognosis in chronic liver disease and cirrhosis [Classics July 16, Updated JNC 8 guidelines for antihypertensive drugs released December 19,

TAJNA KRVAVOG MOSTA PDF

CArvedilol Post-infaRct survIval COntRolled evaluatioN - CAPRICORN

Carvedilol, in addition to standard modern management, would reduce mortality and morbidity compared to placebo in patients with LV dysfunction after recent MI. Continuing requirement for intravenous diuretics or inotropes; uncontrolled heart failure; unstable angina; hypotension systolic blood pressure The original primary endpoint was all-cause mortality. After an interim analysis demonstrated that the study was underpowered to detect a difference in the primary endpoint, the secondary endpoint of all-cause mortality or hospital admissions was adopted as a coprimary endpoint. Carvedilol starting dose of 6. When administered to patients after recent MI who were already receiving ACE inhibitors and standard modern medical therapy, carvedilol appears to have beneficial effects on cardiovascular clinical outcomes.

BANKSMAN HAND SIGNALS PDF

The CAPRICORN trial: Beta-blockers in acute myocardial infarction [Classics Series]

In patients with acute MI and evidence of LV systolic dysfunction, treatment with carvedilol is associated with decreased mortality. Beta-blockers have been used extensively for many decades in the acute and long-term treatment of MI based on RCTs conducted prior to the advent of reperfusion therapies and ACE inhibitors [1] [2] [3]. However, in these studies, patients with heart failure were largely excluded. However, in all these trials, recent MI was an exclusion criteria. With a mean follow-up of 1. The original primary endpoint was all-cause mortality, however given concerns that the trial may be underpowered the primary endpoint was changed from all-cause mortality to all-cause mortality or CV hospital admissions.

78L24 DATASHEET PDF

.

Related Articles